Myriad Genetics Acquires Patent on Another Breast Cancer-Linked Gene
By Ayesha Ahmad,
BioNews
| 01. 23. 2012
Myriad Genetics, a leading US molecular diagnostic company, has been granted exclusive rights to an analysis of the RAD51C gene. Mutations of the gene have been associated with an increased risk for hereditary breast and ovarian cancer and the company now hopes to develop a commercial test for RAD51C.
Mark Capone, president of Myriad, said: 'This intellectual property will enhance our ability to provide patients and health care providers important information on a patient's predisposition to hereditary breast and ovarian cancer'.
Read more...
Image via Flickr.
Related Articles
By Jackie Davalos, Bloomberg | 09.15.2025
Kindbody, one of the largest fertility companies in the US, sought to disrupt egg freezing and IVF by combining spa vibes with Silicon Valley efficiency. The startup raised millions, opened dozens of clinics, and became a billion-dollar unicorn. But its...
By Vuyile Madwantsi, Independent Online | 08.22.2025
Imagine this: a future where parents could choose their baby’s eye colour, height or even intelligence.
Sounds like science fiction, right? But it’s closer than you think.
Let’s start with a simple, human truth: most of us want healthy children...
By Grace Tobin and Kirsten Robb, ABC News Australia | 09.01.2025
A secret audit of a major fertility clinic revealed that almost all of its donor sperm being provided to patients was at high risk of potential mix-ups.
The Queensland Fertility Group (QFG), which is owned by Australia's largest IVF company...
By Kevin Roose, The New York Times | 09.12.2025
The first time I met Eliezer Yudkowsky, he said there was a 99.5 percent chance that A.I. was going to kill me.
I didn’t take it personally. Mr. Yudkowsky, 46, is the founder of the Machine Intelligence Research Institute, a...
